BerGenBio Management

Management criteria checks 2/4

BerGenBio's CEO is Martin Olin, appointed in Sep 2021, has a tenure of 3.08 years. total yearly compensation is NOK10.23M, comprised of 51.5% salary and 48.5% bonuses, including company stock and options. directly owns 0.078% of the company’s shares, worth €29.84K. The average tenure of the management team and the board of directors is 3 years and 1.7 years respectively.

Key information

Martin Olin

Chief executive officer

NOK 10.2m

Total compensation

CEO salary percentage	51.5%
CEO tenure	3.1yrs
CEO ownership	0.08%
Management average tenure	3yrs
Board average tenure	1.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Martin Olin's remuneration changed compared to BerGenBio's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-NOK 155m
Mar 31 2024	n/a	n/a	-NOK 155m
Dec 31 2023	NOK 10m	NOK 5m	-NOK 190m
Sep 30 2023	n/a	n/a	-NOK 226m
Jun 30 2023	n/a	n/a	-NOK 258m
Mar 31 2023	n/a	n/a	-NOK 293m
Dec 31 2022	NOK 11m	NOK 5m	-NOK 302m
Sep 30 2022	n/a	n/a	-NOK 294m
Jun 30 2022	n/a	n/a	-NOK 304m
Mar 31 2022	n/a	n/a	-NOK 309m
Dec 31 2021	NOK 4m	NOK 1m	-NOK 309m

Compensation vs Market: Martin's total compensation ($USD960.34K) is above average for companies of similar size in the German market ($USD499.18K).

Compensation vs Earnings: Martin's compensation has been consistent with company performance over the past year.

CEO

Martin Olin (55 yo)

3.1yrs

Tenure

NOK 10,231,670

Compensation

Mr. Martin Olin serves as Chief Executive Officer at BerGenBio ASA since September 8, 2021. Mr. Olin has been Chairman of the Board at AcouSort AB (publ) since April 28, 2021. He has experience from execut...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Martin Olin	Chief Executive Officer	3.1yrs	NOK 10.23m	0.078% NOK 29.8k
Rune Skeie	Chief Financial Officer	6.6yrs	NOK 3.59m	0.010% NOK 3.8k
Cristina Oliva	Chief Medical Officer	2.5yrs	NOK 5.70m	no data
Graham Morell	Head of IR	no data	no data	no data
Gayle Mills	Chief Business Officer	2.9yrs	NOK 3.39m	no data
Akil Jackson	Medical Director	no data	no data	no data

3.0yrs

Average Tenure

55yo

Average Age

Experienced Management: 7BG0's management team is considered experienced (3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Sally Bennett	Independent Non-Executive Director	3.8yrs	NOK 358.00k	0.012% NOK 4.6k
John Heymach	Member of Scientific Advisory Board	1.7yrs	no data	no data
Shu Kam Mok	Member of Scientific Advisory Board	1.7yrs	no data	no data
Debra Barker	Independent Non-Executive Director	5.6yrs	NOK 344.00k	0.012% NOK 4.6k
Anders Tullgren	Independent Chairman of the Board	2.8yrs	NOK 848.00k	0.055% NOK 21.3k
Enriqueta Font	Member of Scientific Advisory Board	1.7yrs	no data	no data
Solange Peters	Member Scientific Advisory Board	1.7yrs	no data	no data

1.7yrs

Average Tenure

61yo

Average Age

Experienced Board: 7BG0's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.

BerGenBio Management

Management criteria checks 2/4

Key information

Recent management updates

BerGenBio ASA Announces Resignation of Francois Thomas from the Board of Directors

High number of new and inexperienced directors

BerGenBio ASA Announces Board Appointments

BerGenBio ASA Appoints Cristina Oliva as Chief Medical Officer, Effective April 25, 2022

High number of new and inexperienced directors

Recent updates

BerGenBio ASA Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

New major risk - Share price stability

New major risk - Market cap size

New major risk - Financial position

BerGenBio ASA Announces Closure of EU-Solidact Bemcentinib Study Arm in Hospitalized COVID-19 Patients

BerGenBio ASA Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of €240.87 million.

New major risk - Financial position

BerGenBio ASA to Report Q4, 2024 Results on Feb 19, 2025

BerGenBio ASA Announces Full Results of its Phase 2 BGBC008 Study of Bemcentinib and Pembrolizumab in Second Line Non-Small Cell Lung Cancer

New major risk - Shareholder dilution

BerGenBio ASA has completed a Follow-on Equity Offering in the amount of NOK 250 million.

BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO

BerGenBio ASA Announces Resignation of Francois Thomas from the Board of Directors

BerGenBio ASA to Report Q1, 2023 Results on Jun 22, 2023

High number of new and inexperienced directors

BerGenBio ASA Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients

BerGenBio ASA Announces Board Appointments

BerGenBio ASA to Report Q3, 2023 Results on Nov 14, 2023

BerGenBio ASA Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations

BerGenBio ASA Announces First Patient Randomized in Bemcentinib Trial in Eu-Solidact Platform for Hospitalized Covid-19 Patients

BerGenBio ASA Provides Update on Clinical Development

BerGenBio ASA Announces Complete Data Analysis of Accord2 Phase II Bemcentinib Study in Hospitalized Covid-19 Patients - Primary Efficacy Endpoint Met

Bergenbio Presents Bemcentinib Covid-19 Clinical Trial Data At Eccmid 2022

BerGenBio ASA Appoints Cristina Oliva as Chief Medical Officer, Effective April 25, 2022

High number of new and inexperienced directors

BerGenBio ASA Completes Recruitment of Phase II AML Study ((BGBC003)

Chief Executive Officer Richard Godfrey has left the company

BerGenBio ASA Presents Encouraging Combined Data for Bemcentinib from Two Phase II Covid-19 Studies At Eccmid

BerGenBio ASA Updates Preliminary Survival Data from the Ongoing Phase II Study of Bemcentinib

BerGenBio ASA Receives Food and Drug Administration Fast Track Designation for Bemcentinib / Anti-Pd-(L)1 Combination in NSCLC

BerGenBio ASAPresents Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC

BerGenBio ASA to Present Data from Phase I/II Bemcentinib/Erlotinib Combination Trial in NSCLC at ASCO Meeting

BerGenBio ASA Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised Covid-19 Patients

BerGenBio ASA Announces Pre-Clinical COVID-19 Data Presented at Virtual Immunology 2021

BerGenBio ASA Completes Enrolment into Latest Cohort of Phase II Bemcentinib Combination Study in Refractory NSCLC

New 90-day low: €2.90

BerGenBio ASA Announces Start of Phase 1B Trial of Anti-AXL Antibody Tilvestamab (BGB149)

BerGenBio ASA Closes Recruitment into Trial Assessing Bemcentinib in Covid-19 Patients

Revenue in line with expectations

BerGenBio ASA Announces Second Data Monitoring Committee Recommends Continuation of Bergenbio's BGBC020 Trial Assessing Bemcentinib in COVID-19 Patients

BerGenBio ASA Presents an Update from Its Phase II Study of Bemcentinib in Combination with Anti-PD-1 Therapy Pembrolizumab (Bgbc008)

Bergenbio to Present Updates from Ongoing Phase II Bemcentinib Combination Study in Refractory NSCLC At WCLC 2020

New 90-day high: €3.47

BerGenBio ASA to Report Q4, 2020 Results on Feb 10, 2021

BerGenBio ASA to Report Q3, 2021 Results on Nov 16, 2021

New 90-day high: €3.31

BerGenBio ASA Presents Updated Clinical Data from Two Phase II Studies of Bemcentinib in AML and MDS Patients at ASH 2020

BerGenBio ASA Confirms First Patient Enrolled in Phase II Trial Assessing Bemcentinib as Potential Treatment for COVID-19 in India

Revenue in line with expectations

BerGenBio ASA Presents Phase II Bemcentinib Combination Study in NSCLC At Annual SITC Meeting

New 90-day low: €2.52

BerGenBio ASA to Present Clinical Translational Data from the Ongoing Phase II Bemcentinib Combination Study in NSCLC At Annual SITC Meeting

BerGenBio Presents Data on Anti-Axl Antibody Tilvestamab

BerGenBio Announces First Patient Dosed with Bemcentinib in Relapsed Malignant Pleural Mesothelioma Investigator Sponsored Phase IIa Study

Bergenbio ASA Receives Regulatory Approval from the India Regulatory Authority to Proceed with Phase II Clinical Trial to Assess the Efficacy and Safety of Bemcentinib

BerGenBio ASA Receives Approval from Norwegian Regional Ethics Committee for COVID-19 South Africa Trial

New 90-day low: €2.67

BerGenBio ASA to Report Q2, 2020 Results on Aug 18, 2020

First half earnings released

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age